NEW YORK, April 03, 2018 (GLOBE NEWSWIRE) -- According to a new research report titled “Immunoglobulin A Nephropathy Therapeutics - Pipeline Analysis, Clinical Trials & Results, Patents, Designations, Collaborations, Patient Size, and Epidemiology Forecast to 2025” published by P&S Market Research, the study analyzed that the IgA nephropathy therapeutics pipeline comprises of 24 drug candidates in different stages of development. The report also includes epidemiology forecast for IgA Nephropathy for the period 2016 – 2025.
Request for Sample Copy of this Research Report: https://www.psmarketresearch.com/market-analysis/iga-nephropathy-pipeline-analysis/report-sample
The pipeline involves drug candidates that are being developed using specific targets such as a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BlyS). More than three drug candidates are being developed using subcutaneous route of administration.
The drugs candidates that are being developed by the different pharmaceutical companies have demonstrated positive clinical trial results which in-turn increase their further development. For instance, in May 2017 OMS721, a drug candidate developed by the Omeros Corporation demonstrated positive clinical trial results in the treatment of patients with IgA nephropathy. In December 2016, Anthera Pharmaceuticals, Inc. presented positive clinical trial results of blisibimod in 48-week, Phase II study in the treatment of patients with IgA nephropathy.
Browse Full Report with detailed TOC on “IgA Nephropathy Therapeutics Pipeline” at: https://www.psmarketresearch.com/market-analysis/iga-nephropathy-pipeline-analysis
Companies are developing drugs with promising targets for the treatment of the disease. The potential targets may possibly stop or slow the progression of the disease with better efficacy and less side effects. Potential targets such as a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BlyS), melanocortin receptors, and NF-κB signaling can also prove to be effective in IgA nephropathy treatment, since clinical trials of drug candidates meant to act on these targets have shown promising results. This is encouraging companies to further invest in their pipeline to develop drugs acting on new targets, thereby, fueling the growth of the pipeline.
Some of the key players developing drugs for the treatment of IgA nephropathy include Mallinckrodt plc, Merck KGaA, Novartis AG, and Shire plc.
More Reports Published by P&S Market Research
Acne Vulgaris Therapeutics Pipeline Analysis - https://www.psmarketresearch.com/market-analysis/acne-vulgaris-therapeutics-pipeline-analysis
Androgenic Alopecia Therapeutics Pipeline Analysis - https://www.psmarketresearch.com/market-analysis/androgenic-alopecia-therapeutics-pipeline-analysis
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Contact:
P&S Market Research
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com